Resolve Therapeutics
Kirkland, Washington, United States
About Resolve Therapeutics
Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2012)
- Website: resolvebio.com
- Phone: +1 425-576-4100
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/resolve-therapeutics-2499209 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.